Wockhardt has received final approval from the US Food and Drug Administration (USFDA) to market Ranitidine syrup, in the strength of 15 mg.

Ranitidine is used in treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It is also used alongside fexofenadine and other antihistamines for the treatment of skin conditions such as hives.

Recently, the company had received final approval from the US Food and Drug Administration (USFDA) to market Sumatriptan Succinate injectable/ injection, in the strength of 6 mg and 0.5 ml.

Shares of the company closed down Rs 3, or 3.29%, at Rs 88.30. The total volume of shares traded was 20,781 at the BSE (Friday).